Last reviewed · How we verify

R-miniCHOP + Acalabrutinib

Universität des Saarlandes · Phase 3 active Small molecule

R-miniCHOP + Acalabrutinib is a Combination therapy: monoclonal antibody + chemotherapy + BTK inhibitor Small molecule drug developed by Universität des Saarlandes. It is currently in Phase 3 development for B-cell non-Hodgkin lymphoma (phase 3 investigation).

R-miniCHOP chemotherapy combined with acalabrutinib (a Bruton tyrosine kinase inhibitor) targets rapidly dividing lymphoma cells while blocking BTK signaling to enhance anti-tumor immunity.

R-miniCHOP chemotherapy combined with acalabrutinib (a Bruton tyrosine kinase inhibitor) targets rapidly dividing lymphoma cells while blocking BTK signaling to enhance anti-tumor immunity. Used for B-cell non-Hodgkin lymphoma (phase 3 investigation).

At a glance

Generic nameR-miniCHOP + Acalabrutinib
SponsorUniversität des Saarlandes
Drug classCombination therapy: monoclonal antibody + chemotherapy + BTK inhibitor
TargetCD20 (rituximab component); Bruton tyrosine kinase / BTK (acalabrutinib component)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

R-miniCHOP is a reduced-intensity chemotherapy regimen (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) that kills lymphoma cells and activates immune responses. Acalabrutinib selectively inhibits Bruton tyrosine kinase (BTK), a key signaling molecule in B-cell lymphomas and immune cells, thereby reducing tumor cell survival and enhancing anti-tumor T-cell responses. The combination aims to improve efficacy in lymphoma treatment while potentially reducing chemotherapy toxicity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about R-miniCHOP + Acalabrutinib

What is R-miniCHOP + Acalabrutinib?

R-miniCHOP + Acalabrutinib is a Combination therapy: monoclonal antibody + chemotherapy + BTK inhibitor drug developed by Universität des Saarlandes, indicated for B-cell non-Hodgkin lymphoma (phase 3 investigation).

How does R-miniCHOP + Acalabrutinib work?

R-miniCHOP chemotherapy combined with acalabrutinib (a Bruton tyrosine kinase inhibitor) targets rapidly dividing lymphoma cells while blocking BTK signaling to enhance anti-tumor immunity.

What is R-miniCHOP + Acalabrutinib used for?

R-miniCHOP + Acalabrutinib is indicated for B-cell non-Hodgkin lymphoma (phase 3 investigation).

Who makes R-miniCHOP + Acalabrutinib?

R-miniCHOP + Acalabrutinib is developed by Universität des Saarlandes (see full Universität des Saarlandes pipeline at /company/universit-t-des-saarlandes).

What drug class is R-miniCHOP + Acalabrutinib in?

R-miniCHOP + Acalabrutinib belongs to the Combination therapy: monoclonal antibody + chemotherapy + BTK inhibitor class. See all Combination therapy: monoclonal antibody + chemotherapy + BTK inhibitor drugs at /class/combination-therapy-monoclonal-antibody-chemotherapy-btk-inhibitor.

What development phase is R-miniCHOP + Acalabrutinib in?

R-miniCHOP + Acalabrutinib is in Phase 3.

What are the side effects of R-miniCHOP + Acalabrutinib?

Common side effects of R-miniCHOP + Acalabrutinib include Neutropenia, Infection, Diarrhea, Fatigue, Nausea, Bleeding/bruising.

What does R-miniCHOP + Acalabrutinib target?

R-miniCHOP + Acalabrutinib targets CD20 (rituximab component); Bruton tyrosine kinase / BTK (acalabrutinib component) and is a Combination therapy: monoclonal antibody + chemotherapy + BTK inhibitor.

Related